Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Science Daily2d
Potential new therapeutic targets for Huntington's disease
A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...
Discovery of molecular mechanisms offers new targets for Huntington's treatment
A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...
News Medical on MSN1d
Researchers uncover molecular mechanisms driving RNA processing defects in Huntington's disease
A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...
EurekAlert!2d
UC Irvine-led team discovers potential new therapeutic targets for Huntington’s disease
A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington’s disease and link HD with other ...
Crain's Chicago Business3d
AbbVie and rival's ALS drugs both disappoint in study
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...
Outsourcing-pharma3d
Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease ...
Armed robbery in Revesby2d
UC Irvine Team Finds New Targets for Huntington's Disease
A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA ...
pharmaphorum2d
FDA delays decision on Biogen's ALS hope tofersen
The FDA is planning to take an additional three months to review Biogen's experimental therapy for amyotrophic lateral sclerosis (ALS ... its accelerated approval pathway and a priority review ...
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
This confirmation follows the Company's successful efforts to improve its balance sheet by raising new equity and reducing outstanding liabilities. As a result, NeuroSense shareholders' equity now ...